Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 12/20 | 0.57 |
| ▸ | MTTP | P55157 | 11/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13522061 | 0.94 | MTTP (0.55) | NPY2RMTTPMAPTUSP2TP53 | |
| SCHEMBL3128360 | 0.93 | NPY2R (0.65) | NPY2RMTTPMAPTUSP2TP53 | |
| SCHEMBL12174530 | 0.93 | MTTP (0.57) | NPY2RMTTPMAPTUSP2TP53 | |
| SCHEMBL12174410 | 0.91 | MTTP (0.56) | NPY2RMTTP | |
| SCHEMBL3142773 | 0.87 | NPY2R (0.56) | NPY2RMTTPMAPTUSP2TP53 | |
| SCHEMBL12158122 | 0.87 | NPY2R (0.61) | NPY2RMTTPMAPTUSP2TP53 | |
| SCHEMBL13522060 | 0.86 | NPY2R (0.62) | NPY2RMTTPMAPTMAPK1LMNA | |
| SCHEMBL12157618 | 0.86 | NPY2R (0.62) | NPY2RMTTPMAPTUSP2TP53 | |
| SCHEMBL13522053 | 0.86 | MTTP (0.56) | NPY2RMTTP | |
| SCHEMBL12174381 | 0.86 | MTTP (0.61) | NPY2RMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642378-B2 | Lipid lowering biphenylcarboxamides | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-05 | — | — | US | disclosed |
| US-7642378-B2 | Lipid lowering biphenylcarboxamides | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-05 | — | — | US | disclosed |
| US-20080081813-A1 | Lipid Lowering Biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081813-A1 | Lipid Lowering Biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081813-A1 | Lipid Lowering Biphenylcarboxamides | LIPC, PNLIP, LIPA | NPY2R 1487/4885MTTP 20/4885MAPT 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.